Free Trial
NYSE:NUVB

Nuvation Bio Q1 2025 Earnings Report

Nuvation Bio logo
$2.46 +0.19 (+8.37%)
Closing price 05/2/2025 03:59 PM Eastern
Extended Trading
$2.48 +0.02 (+0.61%)
As of 05/2/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nuvation Bio EPS Results

Actual EPS
N/A
Consensus EPS
-$0.16
Beat/Miss
N/A
One Year Ago EPS
N/A

Nuvation Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.42 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nuvation Bio Announcement Details

Quarter
Q1 2025
Time
After Market Closes
Conference Call Date
Wednesday, May 7, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Nuvation Bio Earnings Headlines

URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
Nuvation Bio initiated with an Outperform at Citizens JMP
See More Nuvation Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nuvation Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nuvation Bio and other key companies, straight to your email.

About Nuvation Bio

Nuvation Bio (NYSE:NUVB), a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

View Nuvation Bio Profile

More Earnings Resources from MarketBeat